19.6.14

More Evidence Pours In - Botox Indeed Works For Depression


Botox is a popular aesthetic treatment used to soften the wrinkles on upper face associated with show of emotions like frown, frustration and anger. But lately we have been hearing reports that by softening these expression lines most people also get the added benefit of mood improvement. Theoretically it makes sense, if you look angry, tired and depressed you are likely to act it too. To prove this theory one of the first studies has been conducted at the Hannover Medical School in Germany where the investigators found that treating the facial muscles involved in emotion with Botulinum alleviates depressive symptoms.

Reporting the results of his study at a press conference at the American Psychiatric Association's 2014 Annual Meeting study’s lead investigator Prof. Tillmann Kruger explained, "Our emotions are expressed by facial muscles, which in turn send feedback signals to the brain to reinforce those emotions. Treating facial muscles with Botulinum toxin interrupts this cycle".

Botox For Depression A Novel Approach

A previous open case series showed that depression remitted or improved in patients who had undergone BTX treatment for glabellar frown lines. Following this lead the investigators, decided to study the positive effects on mood post such a treatment. To confirm these results, Dr. Kruger and colleague M. Axel Wollmer, MD, from the Asklepios Clinic North Ochsenzoll in Hamburg, Germany, conducted a randomized, double-blind, placebo-controlled trial of BTX injection as an adjunctive treatment for major depression.

A total of 30 patients with high levels of chronic and treatment-resistant depression were enrolled in the study. Patients were randomly assigned to receive a single injection of BTX or a single injection of saline placebo.
The study's primary end point was a change from baseline in depressive symptoms, as measured by the 17-item Hamilton Depression Rating Scale (HAMD17), during the 16-week study.

Six weeks after a single treatment, the BTX group experienced an average 47.1% reduction in HAMD17 scores vs 9.2% in the placebo group.

The investigators found that the effect improved even further at the end of the study and that treatment-dependent clinical improvement was also reflected in the Beck Depression Inventory and the Clinical Global Impressions Scale.

At the end of the study the investigators concluded that, "This study shows that a single treatment of the glabellar region with Botulinum toxin may shortly accomplish a strong and sustained alleviation of depression in patients who did not improve sufficiently on previous medication. It supports the concept that the facial musculature not only expresses but also regulates mood states."

Dr. Kruger is positively hopeful in commenting that BTX may offer a "novel, effective, well-accepted, and economic therapeutic tool for the treatment of major depression."

These findings have since been replicated in 2 subsequent studies, one by Michelle Magid, MD, and colleagues, which was presented in March at the American Academy of Dermatology 72nd Annual Meeting and reported by Medscape Medical News at that time, and the other by Eric Finzi, MD, PhD, and colleagues, which was published in the May issue of Journal of Psychiatric Research and was also reported by Medscape Medical News.

Dr. Kruger and his colleagues are currently conducting a meta-analysis of the 3 randomized trials in an effort to "further corroborate this novel treatment approach." The researchers are also testing BTX's therapeutic potential in other psychiatric disorders.

Moderating the press conference and commenting on this particular study Jeffrey Borenstein, MD, president and CEO of the Brain and Behavior Research Foundation in New York City and chair of the American Psychiatric Association's Council on Communications, reflected that pursuing new treatments for depression is crucial and that he would like to see this line of research pursued in studies that include larger numbers of patients.

We await further results from such studies that can provide us with further concrete evidence that botox indeed can change how depression is treated and how change in appearance can positively affect human behavior.